MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily 20+ Yr Trsy Bull 3X ETF

T-REX 2X Inverse Tesla Daily Target ETF

ProShares Ultra Silver

VanEck Vectors Junior Gold Miners ETF

Direxion Daily Semicondct Bear 3X ETF

NEOS ETF Trust Kurv Yield Premium Strategy Netflix (NFLX) ETF

GraniteShares 1.5x Long Coinbase Daily ETF

Mast Therapeutics, Inc.

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

GraniteShares 1.5x Long META Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily Gold Miners Bear 3X ETF

Volatility Shares Trust 2x Ether ETF

ProShares Ultra Bloomberg Natural Gas

GraniteShares 2x Long AMZN Daily ETF

Direxion Daily FTSE China Bull 3X ETF

Click Holdings Limited Ordinary Share

Foot Locker Inc.

Kindly MD Inc. Common Stock

Aytu BioPharma Inc.  Common Stock

Gryphon Digital Mining Inc Common Stock

LOBO EV TECHNOLOGIES LTD. Ordinary shares

Next Technology Holding Inc. Ordinary Shares

Siyata Mobile Inc. Common Shares

SolarEdge Technologies Inc. Common Stock

Asset Entities Inc. Class B Common Stock

Incannex Healthcare Limited American Depositary Shares

Microchip Technology Incorporated Common Stock

Crown LNG Holdings Limited Ordinary Shares

Carvana Co. Class A Common Stock

Luminar Technologies Inc.  Class A Common Stock

KLA Corporation Common Stock

Dick's Sporting Goods Inc Common Stock

MicroAlgo Inc. Ordinary Shares

CDW Corporation Common Stock

KKR & Co. Inc. Common Stock

Click here to get full coverage on ARWR: Multiple Value Drivers for Long-Term Growth… - Zacks Small Cap Research

ARWR: Multiple Value Drivers for Long-Term Growth…  Zacks Small Cap Research

ARWR: Multiple Value Drivers for Long-Term Growth… - Zacks Small Cap Research

Click here to get full coverage on ARWR July 18th Options Begin Trading - Nasdaq

ARWR July 18th Options Begin Trading  Nasdaq

ARWR July 18th Options Begin Trading - Nasdaq

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry  simplywall.st

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Click here to get full coverage on Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St  GuruFocus

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus

Click here to get full coverage on Arrowhead Pharma Taps Walgreens Finance Chief to Lead Commercial Stage Transition - Stock Titan

Arrowhead Pharma Taps Walgreens Finance Chief to Lead Commercial Stage Transition  Stock Titan

Arrowhead Pharma Taps Walgreens Finance Chief to Lead Commercial Stage Transition - Stock Titan

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript  Insider Monkey

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus

Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News  GuruFocus

Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Yahoo Finance

Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now  Yahoo Finance

Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential  Yahoo Finance

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Click here to get full coverage on Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus

Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ  GuruFocus

Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company  Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus

Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch  GuruFocus

Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus

Click here to get full coverage on UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News  GuruFocus

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

Click here to get full coverage on Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus

Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight  GuruFocus

Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences - Business Wire

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences  Business Wire

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Release - GuruFocus

Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Release  GuruFocus

Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Release - GuruFocus

Click here to get full coverage on Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus

Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News  GuruFocus

Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2  GuruFocus

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha

Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR)  Seeking Alpha

Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha

Click here to get full coverage on Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results  Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance

Click here to get full coverage on Arrowhead Research: Fiscal Q2 Earnings Snapshot - San Antonio Express-News

Arrowhead Research: Fiscal Q2 Earnings Snapshot  San Antonio Express-News

Arrowhead Research: Fiscal Q2 Earnings Snapshot - San Antonio Express-News

Click here to get full coverage on After-Hours Earnings Report for May 12, 2025 : SPG, DVA, ACHR, BCO, ZI, POWI, RGTI, XENE, ACHC, HTZ, NFE, ARWR - Nasdaq

After-Hours Earnings Report for May 12, 2025 : SPG, DVA, ACHR, BCO, ZI, POWI, RGTI, XENE, ACHC, HTZ, NFE, ARWR  Nasdaq

After-Hours Earnings Report for May 12, 2025 : SPG, DVA, ACHR, BCO, ZI, POWI, RGTI, XENE, ACHC, HTZ, NFE, ARWR - Nasdaq

Click here to get full coverage on Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Revenue $542.7M - marketscreener.com

Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Revenue $542.7M  marketscreener.com

Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Revenue $542.7M - marketscreener.com

Click here to get full coverage on Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week - Yahoo Finance

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week  Yahoo Finance

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - Sarepta Therapeutics

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs  Sarepta Therapeutics

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - Sarepta Therapeutics

Click here to get full coverage on Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug - Stock Titan

Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug  Stock Titan

Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug - Stock Titan

Click here to get full coverage on Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt? - simplywall.st

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?  simplywall.st

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt? - simplywall.st

Click here to get full coverage on Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop - simplywall.st

Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop  simplywall.st

Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop - simplywall.st

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... - Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ...  Yahoo Finance

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... - Yahoo Finance

Click here to get full coverage on Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR)  Seeking Alpha

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha

Click here to get full coverage on Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal - Investor's Business Daily

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal  Investor's Business Daily

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal - Investor's Business Daily

Click here to get full coverage on Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket  Benzinga

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga

Click here to get full coverage on ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report  TradingView

ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Click here to get full coverage on Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News - GuruFocus

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News  GuruFocus

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News - GuruFocus

Click here to get full coverage on Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Yahoo Finance

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases  Yahoo Finance

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Yahoo Finance

Click here to get full coverage on Arrowhead Research: Fiscal Q2 Earnings Snapshot - MySA

Arrowhead Research: Fiscal Q2 Earnings Snapshot  MySA

Arrowhead Research: Fiscal Q2 Earnings Snapshot - MySA

Click here to get full coverage on Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential  Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Click here to get full coverage on Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results  Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Business Wire

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results  Business Wire

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics  Business Wire

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire

Click here to get full coverage on Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - simplywall.st

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses  simplywall.st

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - simplywall.st

Click here to get full coverage on Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results  Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Business Wire

Click here to get full coverage on Cantor Fitzgerald maintains Overweight on Arrowhead stock - Investing.com

Cantor Fitzgerald maintains Overweight on Arrowhead stock  Investing.com

Cantor Fitzgerald maintains Overweight on Arrowhead stock - Investing.com

Click here to get full coverage on Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Business Wire

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)  Business Wire

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Business Wire

Click here to get full coverage on Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - Business Wire

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity  Business Wire

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - Business Wire

Click here to get full coverage on Citi cuts Arrowhead stock target to $17, maintains neutral By Investing.com - Investing.com Nigeria

Citi cuts Arrowhead stock target to $17, maintains neutral By Investing.com  Investing.com Nigeria

Citi cuts Arrowhead stock target to $17, maintains neutral By Investing.com - Investing.com Nigeria

Click here to get full coverage on Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highl - GuruFocus

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highl  GuruFocus

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highl - GuruFocus

Click here to get full coverage on Arrowhead (ARWR) Announces CFO Transition as Ken Myszkowski Reti - GuruFocus

Arrowhead (ARWR) Announces CFO Transition as Ken Myszkowski Reti  GuruFocus

Arrowhead (ARWR) Announces CFO Transition as Ken Myszkowski Reti - GuruFocus

Click here to get full coverage on Arrowhead Pharma earnings beat by $3.20, revenue topped estimates - Investing.com

Arrowhead Pharma earnings beat by $3.20, revenue topped estimates  Investing.com

Arrowhead Pharma earnings beat by $3.20, revenue topped estimates - Investing.com

Click here to get full coverage on Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)  Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on ARWR: Two Obesity Assets to Enter the Clinic in 2025… - Yahoo Finance

ARWR: Two Obesity Assets to Enter the Clinic in 2025…  Yahoo Finance

ARWR: Two Obesity Assets to Enter the Clinic in 2025… - Yahoo Finance

Click here to get full coverage on Arrowhead's Rare Disease Drug Plozasiran Gets FDA Review After Strong Phase 3 Results - Stock Titan

Arrowhead's Rare Disease Drug Plozasiran Gets FDA Review After Strong Phase 3 Results  Stock Titan

Arrowhead Pharmaceuticals Inc (ARWR)

Price Chart

Key Statistics

Technicals

About ARWR

Latest News

ARWR: Multiple Value Drivers for Long-Term Growth… - Zacks Small Cap Research

ARWR July 18th Options Begin Trading - Nasdaq

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers